Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EpiCept Corporation
This is a phase II, multicenter, randomized, placebo-controlled, parallel group study of EpiCept™ NP-1 Topical Cream (amitriptyline 4%/ketamine 2%) in approximately 200 patients with chronic pain in the lower extremities due to diabetic peripheral neuropathy (DPN).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may not be if
Clinically significant intercurrent illness (e.g., endocrine, cardiac, hepatic, renal, neurologic, hematologic, skeletal) that the investigator determines could interfere with the efficacy or safety assessments in this study